Seth Wander, MD

Videos

Selecting CDK4/6 Inhibitors for Patients With ER-Positive Early Breast Cancer

12/07/2023

Cynthia Ma, MD, leads part 2 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting CDK4/6 inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 2 of...

12/07/2023

Oncology

Videos

Selecting Chemotherapy for Patients With ER-Positive Early Breast Cancer

11/30/2023

Cynthia Ma , MD;

Neelima Vidula , MD;

Seth Wander , MD;

Cynthia Ma, MD, leads part 1 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting chemotherapy as a treatment option for patients with ER-positive...

Cynthia Ma, MD, leads part 1 of...

11/30/2023

Oncology

Conference Coverage

Vepdegestrant Plus Palbociclib for Patients With ER-Positive, HER2-Negative Advanced Breast Cancer

01/04/2024

Seth Wander , MD;

Seth Wander, MD, PhD, discussed results from the phase 1b cohort of a phase 1/2 clinical trial, demonstrating that vepdegestrant plus palbociclib is clinically effective among patients with heavily pretreated, ER-positive, HER2-negative...

Seth Wander, MD, PhD, discussed...

01/04/2024

Oncology

Videos

Considerations for Endocrine Therapy for Patients With ER-Positive Early Breast Cancer

12/12/2023

Seth Wander , MD;

Cynthia Ma , MD;

Neelima Vidula , MD;

Cynthia Ma, MD, leads part 4 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for endocrine therapy for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 4 of...

12/12/2023

Oncology

Videos

Selecting PARP Inhibitors for Patients With ER-Positive Early Breast Cancer

12/12/2023

Cynthia Ma , MD;

Neelima Vidula , MD;

Seth Wander , MD;

Cynthia Ma, MD, leads part 3 of a 4-part roundtable panel discussion with Neelima Vidula, MD, and Seth Wander, MD, in which the panelists discuss considerations for selecting PARP inhibitors for patients with ER-positive early breast cancer.

Cynthia Ma, MD, leads part 3 of...

12/12/2023

Oncology